Evaluation Of Present Day Treatment Of Peptic Ulcer

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/111139/1/j.1532-5415.1953.tb01110.x.pd

Precancerous gastric disease

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44422/1/10620_2005_Article_BF02231503.pd

Discussion of foregoing papers

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44421/1/10620_2005_Article_BF02235684.pd

Therapeutic trial of silicone in peptic ulcer

In a controlled double-blind trial of the therapeutic effectiveness of silicone in patients with duodenal ulcer, the silicone tested was shown to be slightly less effective than placebo medication. The relatively good early response of chronically recurring ulcer disease appeared to be due to the emotional impact of “a new treatment of ulcers.”Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44434/1/10620_2005_Article_BF02232021.pd

Gastroscopic findings and fecal blood loss following aspirin administration

A study of 19 healthy young male subjects (Group 1) was made in which a correlation of aspirin ingestion, fecal blood loss, blood salicylate levels, prothrombin concentrations, and ABO blood groups was sought. An initial 4-day control period was followed by a 4-day test period during which subjects ingested 650 mg aspirin with each meal and at bedtime. Gastroscopy with photography was done on Day 1 and Day 7. Daily fecal blood loss was quantitated using the 51-chromium tagged erythrocyte method. Sixteen patients (Group 2) with a variety of upper gastrointestinal disorders underwent gastroscopy and photography before and after the acute ingestion of aspirin. Results reveal: (1) Aspirin produced petechiae in 4 of 18 subjects and a hemorrhagic gastritis in 1 of 18 in Group 1, (2) aspirin produced no visible lesions in the 16 subjects in Group 2, (3) the mean fecal blood loss during the control period was 0.38±0.35 g/24 hr and rose to 1.54±1.42 g/24 hr (P<0.01) during aspirin ingestion, (4) no correlation between normal or abnormal gastroscopic findings and fecal blood loss was apparent, and (5) no correlation between blood salicylate levels, prothrombin concentrations, and gastroscopic findings or fecal blood loss was detected.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44370/1/10620_2005_Article_BF02235965.pd

A STEROID-INDUCED GASTRIC ULCER

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/32509/1/0000599.pd

Toxic dilatation of the colon in granulomatous colitis

Toxic dilatation of the colon usually occurs in ulcerative colitis, but may also occur in amebic and granulomatous colitis. Two cases of toxic dilatation of the colon in granulomatous colitis are compared to 2 previously reported cases. Toxic dilatation may occur after 7 months or 7 years from the onset of symptoms and may occur on more than one occasion. Granulomatous colitis is more common complication than is generally appreciated.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44372/1/10620_2005_Article_BF02232877.pd

Protein-losing gastroenteropathy: Concepts derived from lymphangiography

Lymphangiograms in 2 patients with protein-losing gastroenteropathy showed abnormalities of both abdominal and lower-extremity lymphatics.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44359/1/10620_2005_Article_BF02237631.pd

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and induce apoptosis of cancer cell lines in vitro and can also inhibit growth of pancreatic cancer xenografts in vivo. Thirty-six patients with advanced pancreatic cancer received once daily oral treatment with seocalcitol with dose escalation every 2 weeks until hypercalcaemia occurred, following which patients continued with maintenance therapy. The most frequent toxicity was the anticipated dose-dependent hypercalcaemia, with most patients tolerating a dose of 10–15 μg per day in chronic administration. Fourteen patients completed at least 8 weeks of treatment and were evaluable for efficacy, whereas 22 patients were withdrawn prior to completing 8 weeks' treatment and in 20 of these patients withdrawal was due to clinical deterioration as a result of disease progression. No objective responses were observed, with five of 14 patients having stable disease in whom the duration of stable disease was 82–532 days (median=168 days). The time to treatment failure (n=36) ranged from 22 to 847 days, and with a median survival of approximately 100 days. Seocalcitol is well tolerated in pancreatic cancer but has no objective anti-tumour activity in advanced disease. Further studies are necessary to determine if this agent has any cytostatic activity in this malignancy in minimal disease states

A simplified multiple-retrieving small-bowel biopsy tube

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44440/1/10620_2005_Article_BF02231909.pd